ABSTRACT
BACKGROUND AND PURPOSE: Fingolimod is a drug approved for treatment of relapsing-remitting multiple sclerosis (RRMS) that exerts its effects via sequestering lymphocytes within the lymph nodes. The drug, acting on the sphingosine-1-phosphate pathway, is involved in a plethora of processes and, to date, its mechanism of action is not completely understood. Recently, it has been demonstrated that Fingolimod increases the expression of transcription factor NR4A2 in murine brain. NR4A2 belongs to nuclear receptor family 4, group A (NR4A) along with NR4A1 and NR4A3. The role of NR4A2 in the pathogenesis of multiple sclerosis is already known and supported by its down-regulation observed in blood obtained from patients with RRMS compared with healthy controls (HCs). It is notable that NR4A2 impairment is reversed in patients with RRMS during pregnancy, which represents a transitory state of immune tolerance, associated with reduced disease activity. An inverse correlation between NR4A2 gene expression levels and clinical parameters indicates that more aggressive forms of the disease are characterized by lower levels of NR4A2. METHODS: Gene expression levels of NR4A in blood obtained from HCs, treatment-naive (T0) and Fingolimod-treated patients with RRMS were evaluated to determine their contribution to drug response. RESULTS: Gene expression levels of NR4A were down-regulated in T0 patients compared with HCs. Patients treated with Fingolimod for >2 years were characterized by higher levels of NR4A2 compared with the T0 group, approaching those of HCs. NR4A1 and NR4A3 levels were not altered. CONCLUSIONS: Involvement of the NR4A family in the pathogenesis of multiple sclerosis and a role of Fingolimod in the recovery from NR4A2 deficit can be hypothesized based on our data.
Subject(s)
Fingolimod Hydrochloride/therapeutic use , Gene Expression , Immunosuppressive Agents/therapeutic use , Multiple Sclerosis/genetics , Nuclear Receptor Subfamily 4, Group A, Member 1/genetics , Adolescent , Adult , Aged , Animals , Down-Regulation , Female , Humans , Male , Mice , Middle Aged , Multiple Sclerosis/drug therapy , Young AdultABSTRACT
Multiple Sclerosis (MS) is a heterogeneous disease and a variable percentage of patients are non-responders to common treatment. Early diagnosis of non-responders allows change to a more useful therapy for the patient and better allocates a large amount of financial resources. Quantification of Neutralizing antibodies (Nabs) and of biological activity of IFN-ß are recognized approaches to identify immuno-pharmacological non-responders. A consistent number of studies have demonstrated that quantification of Myxovirus-induced protein A (MxA) is a valid biomarker to detect immune-pharmacological non responders after one year of treatment. Persistent high titre of Nabs and absence of biological activity predict abolition of IFN-ß effects in disease activity measured through MRI, number of relapses and disability. Guidelines and flow-charts including both Nabs and MxA quantification are presented.
Subject(s)
Interferon-beta/therapeutic use , Multiple Sclerosis/drug therapy , Multiple Sclerosis/immunology , Antibodies, Neutralizing/blood , Biomarkers/analysis , Humans , Myxovirus Resistance Proteins/analysis , Myxovirus Resistance Proteins/genetics , RNA, Messenger/analysis , RNA, Messenger/geneticsABSTRACT
BACKGROUND: Neutralising antibodies (NAb) to interferon beta (IFN beta) are associated with a reduced bioactivity and efficacy of IFN beta in multiple sclerosis (MS). Unclear is how to apply IFN beta bioactivity measurements (quantification of Myxovirus resistance protein A (MxA) mRNA) in clinical practice. OBJECTIVES: To evaluate value and feasibility of IFN beta bioactivity measurement with a single MxA mRNA measurement for screening and a second measurement before and after IFN beta administration for definite confirmation of IFN beta bioactivity status. METHODS: In 79 MS patients MxA mRNA expression was determined 4 hours after IFN beta administration. If inadequate, MxA mRNA expression testing was repeated 3 months afterwards, comparing post- and pre injection samples to determine whether IFNb bioactivity was persistently lacking. MxA mRNA expression was compared to NA beta titres, determined by the cytopathic effect assay (CPE). RESULTS: NAb titres correlated significantly with MxA mRNA expression and MxA mRNA induction. Of all screened patients, only one patient had adequate MxA mRNA expression and high NAb titres simultaneously. Of the biological non-responders at second measurement (21/55), 17 (81%) were high-titre NAb positive, 1 (5%) was low-titre NAb positive and 3 (14%) were NAb negative. Without considering the pre-injection measurement, two more NAb negative patients would have tested negative for IFN beta bioactivity, emphasizing the need of a pre-injection sample. CONCLUSIONS: Our data suggest that for IFN beta bioactivity screening a single post-injection measurement seems reasonable. However, MxA induction measurement based on both pre- and post-IFN beta injection samples at second measurement is somewhat more precise in determining ultimate IFN beta bioactivity status.
Subject(s)
Drug Monitoring/methods , Immunologic Factors/administration & dosage , Immunologic Factors/immunology , Interferon-beta/administration & dosage , Interferon-beta/immunology , Multiple Sclerosis, Relapsing-Remitting/drug therapy , Adult , Antibodies/immunology , Antibodies/pharmacology , Feasibility Studies , Female , GTP-Binding Proteins/genetics , GTP-Binding Proteins/immunology , Gene Expression Regulation, Viral/drug effects , Gene Expression Regulation, Viral/immunology , Humans , Immunoassay/methods , Male , Middle Aged , Multiple Sclerosis, Relapsing-Remitting/immunology , Myxovirus Resistance Proteins , Neutralization Tests , RNA, Messenger/metabolism , Young AdultABSTRACT
BACKGROUND: The cytokine interferon beta (IFNbeta) is successfully used in the treatment of multiple sclerosis (MS), although there is a high degree of variability in the response. A common mechanism involved in the modulation of responsiveness to cytokines is represented by regulation of their receptor expression through autocrine ligand-mediated loops. The present study is aimed at investigating the regulation of IFNalpha/beta receptor (IFNAR) during IFNbeta therapy in patients with MS and at correlating it with the biologic responsiveness to the cytokine. METHODS: Quantitative PCR measurements of IFNAR-1 and the three IFNAR-2 isoforms were performed in 141 patients after short-term and long-term treatment. Patients were also regularly screened for anti-IFNbeta neutralizing antibodies (NAbs). IFN-inducible myxovirus resistance protein A messenger RNA was used as an indicator of bioactivity. RESULTS: Pretreatment levels of IFNAR-2 in patients were lower overall than in controls (p = 0.038), and high levels correlated with greater bioactivity. Upon prolonged treatment, NAb-negative patients displayed a state of decreased transmembrane IFNAR-2 expression (p < or = 0.025), whereas levels of soluble IFNAR-2 were slightly increased (p < 0.0001). The presence of NAbs reversed these effects (p < or = 0.0056). In NAb-positive patients, pretreatment expression levels of both transmembrane IFNAR-2 isoforms were significantly lower than in NAb-negative patients (p < or = 0.0089). CONCLUSIONS: Findings show that interferon-alpha/beta receptor (IFNAR)-2 isoforms are important regulators of the responsiveness to endogenous and systemically administered interferon beta (IFNbeta). They show a dual action, agonistic and antagonistic, that influences both the magnitude and the nature of the biologic response to IFNbeta. Levels of IFNAR-2 are regulated with the aim of keeping the body in a state of equilibrium, even when nonphysiologic stimuli are present.
Subject(s)
Drug Resistance/genetics , Interferon-beta/pharmacology , Multiple Sclerosis/drug therapy , Multiple Sclerosis/immunology , Receptor, Interferon alpha-beta/drug effects , Receptor, Interferon alpha-beta/genetics , Alternative Splicing/drug effects , Alternative Splicing/genetics , Alternative Splicing/immunology , Cell Membrane/chemistry , Cell Membrane/genetics , Cell Membrane/immunology , Down-Regulation/drug effects , Down-Regulation/genetics , Down-Regulation/immunology , Drug Resistance/immunology , Female , Gene Expression Regulation/drug effects , Gene Expression Regulation/genetics , Gene Expression Regulation/immunology , Homeostasis/drug effects , Homeostasis/genetics , Homeostasis/immunology , Humans , Immunologic Factors/pharmacology , Immunologic Factors/therapeutic use , Interferon-beta/therapeutic use , Male , Multiple Sclerosis/physiopathology , Polymerase Chain Reaction , Protein Isoforms/drug effects , Protein Isoforms/genetics , Protein Isoforms/immunology , Protein Structure, Tertiary/drug effects , Protein Structure, Tertiary/genetics , RNA, Messenger/analysis , RNA, Messenger/metabolism , Receptor, Interferon alpha-beta/immunology , Retrospective Studies , Up-Regulation/drug effects , Up-Regulation/genetics , Up-Regulation/immunologyABSTRACT
BACKGROUND: Prolonged therapy with interferon beta (IFN beta) often leads to the development of anti-IFN beta binding antibodies (BAbs). A subset of the BAbs is of a neutralizing nature (neutralizing antibodies, NAbs) and is associated with reduced clinical efficacy of therapy. Myxovirus-resistance-protein A (MxA) has proven to be a reliable biomarker of IFN beta bioactivity. We analyzed the prognostic value of MxA mRNA, NAbs, and BAbs on the risk of having a new relapse in IFN beta-treated patients. METHODS: A 3-year study was conducted in 137 IFN beta-treated patients. Blood samples for BAbs, NAbs, and MxA mRNA measurements were taken after 12 +/- 3 months of therapy. Analysis of relapse-free survival (RFS) was performed for all measures by using known thresholds, generating "positive" and "negative" groups. Also, time between sampling and following relapse and risk of new relapses were calculated. RESULTS: The MxA-negative group showed poorer RFS rates than the MxA-positive group [p < 0.0001, hazard ratio (HR) = 2.87]. Likewise, the NAb-positive group showed poorer RFS rates than the NAb-negative group (p =0.0013; HR = 2.49). On the contrary, BAb measurement did not show a clear clinical significance. CONCLUSIONS: Findings indicate that measurements of both myxovirus-resistance-protein A (MxA) and neutralizing antibodies (NAbs) predict the risk of new relapses; however, the slightly stronger prognostic significance of MxA mRNA and the easier method for it measurement make MxA mRNA the preferred biomarker for monitoring interferon beta (IFN beta)-treated patients. This information can be used to better tailor treatment to the individual patient with MS.
Subject(s)
GTP-Binding Proteins/genetics , Interferon-beta/pharmacology , Multiple Sclerosis/diagnosis , Multiple Sclerosis/drug therapy , RNA, Messenger/blood , Adolescent , Adult , Antibodies/analysis , Antibodies/blood , Antibodies/immunology , Biomarkers/analysis , Biomarkers/blood , Disease-Free Survival , Drug Resistance/immunology , Female , Humans , Immunologic Factors/pharmacology , Immunologic Factors/therapeutic use , Interferon-beta/therapeutic use , Leukocytes, Mononuclear/metabolism , Male , Middle Aged , Multiple Sclerosis/blood , Myxovirus Resistance Proteins , Predictive Value of Tests , Prognosis , RNA, Messenger/analysis , Recurrence , Retrospective Studies , Risk Factors , Treatment OutcomeABSTRACT
There are two commonly employed types of bioassays for the detection of neutralizing antibodies (NAbs) against interferon-beta (IFNbeta): the cytopatic effect assay (CPE), and the MxA (myxovirus resistance protein A) protein assay (MPA). This article describes a bioassay based on the real time PCR measurement of mRNA that results from the induction, in cultured human cells, of the MxA gene by IFNbeta. Serum samples from 104 patients with multiple sclerosis (MS) treated with IFNbeta were tested for NAbs using our real time PCR bioassay. NAbs also were measured in the same specimens by the MPA assay and CPE assay. The calibration range of the real time PCR bioassay is 0.125-30 LU/mL. The range of the intra- and inter-assay variations (coefficients of variation in log(10)) were 4.05% (range 0.88%-7.90%) and 4.42% (range 0.31%-9.15%), respectively. Samples of the three commercial preparations of IFNbeta-1a and -1b were measured showing dose-response curves parallel to that of the NIH reference IFNbeta (mean SD at the midpoint of the dose-response curve=5%). In addition, the assay was robust with respect to number of cells plated (i.e., increasing cell densities from 12x10(3)/well to 384x10(3)/well resulted in 3.03% variability in MxA expression normalized with glyceraldehyde-3 phosphate dehydrogenase). NAbs titers measured were closely comparable to those obtained by the MPA [r(spearman)=0.899; 89% of observed agreements; K=0.779] and the CPE [r(spearman)=0.7899); 86%; K=0.729] assays. Despite the obvious disadvantage of cost, when carried out according to quality assurance guidelines for molecular diagnostics the new MxA gene-expression assay (MGA) has significant advantages over the other methods for testing NAbs: it has excellent reliability and reproducibility, and utilizes equipment and methodologies already accessible in many clinical laboratories.
Subject(s)
Antibodies/blood , Biological Assay/methods , Immunologic Factors/immunology , Interferon-beta/immunology , Multiple Sclerosis/immunology , Reverse Transcriptase Polymerase Chain Reaction/methods , Antibodies/immunology , Biological Assay/standards , Calibration , Cell Line, Tumor , Cytopathogenic Effect, Viral/drug effects , Dose-Response Relationship, Drug , Dose-Response Relationship, Immunologic , Encephalomyocarditis virus/drug effects , Encephalomyocarditis virus/pathogenicity , GTP-Binding Proteins/biosynthesis , GTP-Binding Proteins/genetics , Humans , Immunologic Factors/pharmacology , Immunologic Factors/therapeutic use , Interferon beta-1a , Interferon beta-1b , Interferon-beta/pharmacology , Interferon-beta/therapeutic use , Multiple Sclerosis/drug therapy , Myxovirus Resistance Proteins , Neutralization Tests/methods , RNA, Messenger/biosynthesis , Reference Standards , Reproducibility of Results , Reverse Transcriptase Polymerase Chain Reaction/standards , Sensitivity and Specificity , Time Factors , Up-Regulation/drug effectsABSTRACT
Biological activity of interferon-beta (IFNbeta) can be assessed by measuring IFN-stimulated genes (ISGs). Among them, myxovirus resistance protein A (MxA) appears to have the highest specificity, but it has no role in the pathogenesis of multiple sclerosis (MS). To investigate the reliability of MxA as a biomarker, we compared its expression to that of two other ISGs: TNF-related apoptosis-inducing ligand (TRAIL) and X-linked inhibitor of apoptosis factor-1 (XAF-1). Both were shown to be involved in immunoregulatory mechanisms and might play a role in MS. Quantitative-PCR measurements were performed in peripheral blood mononuclear cells from 73 MS patients after short-term and long-term treatment with IFNbeta. A time-dependent response for multiple ISGs was observed in all patients after short-term treatment. In contrast, long-term treatment induced concurrent inhibition of ISGs in 12.3% (9/73) of patients, in whom neutralizing antibodies (NAbs) were detectable. Besides, 22% (16/73) of chronically treated patients showed a non-NAbs-related abrogation of TRAIL expression. In summary, 1) MxA expression was significantly higher than both TRAIL and XAF-1, and 2) MxA was the most sensitive gene to detect decreased bioavailability due to NAbs. These findings identify MxA as an appropriate biomarker for IFNbeta, although there is no evidence for a functional role of it in MS.
Subject(s)
Apoptosis Regulatory Proteins/genetics , GTP-Binding Proteins/genetics , Interferon-beta/therapeutic use , Membrane Glycoproteins/genetics , Multiple Sclerosis, Relapsing-Remitting/drug therapy , Multiple Sclerosis, Relapsing-Remitting/immunology , Neoplasm Proteins/genetics , Tumor Necrosis Factor-alpha/genetics , Adaptor Proteins, Signal Transducing , Adult , Apoptosis Regulatory Proteins/blood , Biomarkers/blood , Female , GTP-Binding Proteins/blood , Gene Expression Regulation/immunology , Humans , Interferon beta-1b , Intracellular Signaling Peptides and Proteins , Male , Membrane Glycoproteins/blood , Multiple Sclerosis, Relapsing-Remitting/blood , Multiple Sclerosis, Relapsing-Remitting/genetics , Myxovirus Resistance Proteins , Neoplasm Proteins/blood , RNA, Messenger/genetics , Reference Values , TNF-Related Apoptosis-Inducing Ligand , Time FactorsABSTRACT
To date, inter- and intra-laboratory consistency of binding assays for measuring anti-interferon (IFN)beta antibodies has not been assessed. In this investigation, two independent laboratories tested a library of 80 serum specimens obtained from multiple sclerosis (MS) patients treated with IFNbeta. For binding antibodies (BAbs) evaluations, each laboratory used both a capture-ELISA (cELISA) and an enzyme-immuno-assay (EIA), which is commercially available. Samples were also tested for neutralizing antibodies (NAbs). Data demonstrated good intra-laboratory reliability (r(pearson) > or = 0.86), and a good overall agreement between the results obtained from the two centers, using both the cELISA (69/80 of observed agreements) and the EIA (67/80). Accordingly, kappa coefficients (K) showed good concurrence (K > or = 0.651). There was also substantial agreement between cELISA and EIA measurements, as performed in both centers (Orbassano, 66/80, K = 0.631; Basel, 70/80, K = 0.717). However, by comparing NAbs and BAbs titers obtained with both assays, we found that a high degree of BAb-negative samples were positive in NAb-assay. Thus, our study does not support the usefulness of ELISA-based BAb assays as a screening tool for NAbs. Otherwise, BAb-assays can be used as a confirmation test, indicating that the decrease of the biological effects is due to antibodies. In this context, both ELISA-based assays are equally reliable techniques.
Subject(s)
Adjuvants, Immunologic/therapeutic use , Enzyme-Linked Immunosorbent Assay/methods , Interferon-beta/immunology , Interferon-beta/therapeutic use , Multiple Sclerosis/drug therapy , Multiple Sclerosis/immunology , Antibodies/blood , Cell Line, Tumor , Encephalomyocarditis virus/immunology , Enzyme-Linked Immunosorbent Assay/standards , Humans , Immunoassay/methods , Immunoassay/standards , Interferon beta-1a , Interferon beta-1b , Lung Neoplasms , Mass Screening/methods , Mass Screening/standards , Neutralization Tests , Reproducibility of ResultsABSTRACT
Relapsing-remitting multiple sclerosis (MS) has a very fluctuating course and responsiveness to interferon beta (IFN-beta) treatment in each patient is extremely difficult. Agreement exists about the negative role of neutralising antibodies (NAbs) on clinical efficacy and markers of IFN-beta bioavailability have been studied; no guidelines exist yet about what to do when a patient becomes NAbs positive or IFN biological activity is lost. In this study 405 MS patients have been longitudinally studied for NAbs and MxA expression. A spontaneous disappearance of NAbs was observed in a few patients with low antibody titre; according to the clinical course, a therapeutic modification has been made in patients persistently NAbs positive; in these patients NAbs persisted over time despite the interruption of IFN therapy.
Subject(s)
Antibodies/blood , GTP-Binding Proteins/blood , Interferon-beta/immunology , Multiple Sclerosis, Relapsing-Remitting/diagnosis , Multiple Sclerosis, Relapsing-Remitting/immunology , Adjuvants, Immunologic/pharmacokinetics , Adjuvants, Immunologic/therapeutic use , Antibodies/genetics , Antibody Formation , Antibody Specificity , Biological Availability , GTP-Binding Proteins/genetics , Humans , Interferon-beta/pharmacokinetics , Interferon-beta/therapeutic use , Longitudinal Studies , Multiple Sclerosis, Relapsing-Remitting/blood , Multiple Sclerosis, Relapsing-Remitting/drug therapy , Myxovirus Resistance Proteins , Prognosis , RNA, Messenger/analysis , Treatment OutcomeABSTRACT
This study is the first to evaluate biological response to first injections of interferon-beta (IFNbeta) in patients with multiple sclerosis. MxA mRNA was measured in 96 patients receiving IFNbeta-1a (Avonex, n=32), IFNbeta-1b (Betaferon, n=19), IFNbeta-1a (Rebif) 22 microg (n=30), or IFNbeta-1a 44 microg (n=15). Patients were analysed before, 3 and 24 h after the first injection, and 12 h after the second administration. Results showed that up-regulation was evident within 3 h of IFNbeta injection, peaked 12 h after injection, and progressively declined 24 h after administration. The cumulative responses were similar after a single administration, regardless of product/dose. Moreover, data indicate that the abolition of the biological activity detected during IFNbeta therapy is due to underlying phenomena (e.g., neutralizing antibodies), because all patients were constitutively responders to IFNbeta at treatment initiation.
Subject(s)
GTP-Binding Proteins/metabolism , Immunologic Factors/administration & dosage , Interferon-beta/administration & dosage , Multiple Sclerosis/metabolism , Adult , Area Under Curve , Demography , Disability Evaluation , Dose-Response Relationship, Drug , Female , GTP-Binding Proteins/drug effects , GTP-Binding Proteins/genetics , Humans , Immunologic Factors/therapeutic use , Interferon beta-1a , Interferon beta-1b , Interferon-beta/immunology , Interferon-beta/therapeutic use , Male , Middle Aged , Multiple Sclerosis/drug therapy , Myxovirus Resistance Proteins , RNA, Messenger/drug effects , RNA, Messenger/metabolism , Reverse Transcriptase Polymerase Chain Reaction/methods , Time FactorsABSTRACT
BACKGROUND: MxA gene expression is one of the most appropriate markers of biological activity of exogenous interferon (IFN) beta. METHODS: We quantified MxA mRNA for five consecutive days in 62 patients treated with IFN beta (16, Avonex; 10, Betaferon; 24, Rebif 22; 12, Rebif 44), by quantitative-competitive polymerase chain reaction. Every three months, IFN beta induced neutralising antibodies (NAbs) were evaluated in sera using a cytopathic effect assay. RESULTS: Two categories of patients were identified: one group (49/62) had a sharp post-injection increase in MxA expression (defined as "IFN beta biological responder"), whereas the other group (13/62) had no MxA induction after IFN beta administrations (defined as "IFN beta biological non-responder"). In 11/13 biological non-responders, the persistent presence of NAbs correlated with abolished biological activity, independently of treatment regimen. The two remaining IFN beta biological non-responders were NAb-. Among the 49 IFN beta biological responders, biological activity was comparable between the four preparations on day 2 and 3 (+12 and +36 hours post-injection), but it was greater in Betaferon and both Rebif preparations on day 1, 4, and 5. In biological responders treated three times a week, only 82% (59/72) of injections were considered effective, compared with 100% (13/13) of Avonex injections. CONCLUSION: Our results suggest that an optimal IFN beta regimen is not yet available: Avonex, given once a week, shows lower cumulative biological activity. On the other hand, both Betaferon and Rebif, given three times a week, show 18% biologically ineffective injections and higher risk of developing NAbs, which abolish biological activity.